Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19245610 | 0.96 | PPARD (0.45) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL16625358 | 0.91 | PPARD (0.49) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL11577479 | 0.85 | PPARD (0.59) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL16625359 | 0.84 | PPARD (0.63) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL8113767 | 0.84 | PPARD (0.63) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL16625354 | 0.84 | PPARD (0.50) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL16625363 | 0.83 | PPARD (0.57) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL17019847 | 0.81 | PPARD (0.59) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL6187009 | 0.79 | TSHR (0.50) | PPARDTSHRACHETDP1 | |
| SCHEMBL19245711 | 0.78 | PPARD (0.59) | PPARDTSHRMEN1GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847201-B1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | UNIV QUEENSLAND (AU) | 2017-08-16 | — | — | EP | disclosed |
| US-9200020-B2 | 6-oxopurine phosphoribosyltransferase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-9200020-B2 | 6-oxopurine phosphoribosyltransferase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-09 | — | — | US | disclosed |
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | HPRT1, APRT, TPMT | PPARD 3578/4885TSHR 3777/4885MEN1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.